---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-234848"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-05-21T21:05:15+00:00"
generated_at: "2026-05-21T21:47:59.586901+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs

## Summary
- OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
- Among 19 evaluable patients, 13 showed tumor shrinkage; 2 confirmed + 1 unconfirmed partial response.
- Most common TRAEs: dysgeusia (81% any grade), anemia (38%; 6% grade 3), neutropenia (34%; 28% grade 3).
- Dose-proportional PK; at ≥6 mg steady-state concentrations exceeded preclinical efficacy targets.
- Data presented at ASCO May 30; also presenting OPERA-02 Phase 3 trial-in-progress poster.

## SEC filing metadata
- accession: 0001193125-26-234848
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-05-21T21:05:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/0001193125-26-234848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/olma-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-234848
- JSON: https://secwatch.observer/filing/0001193125-26-234848.json
- Plain text: https://secwatch.observer/filing/0001193125-26-234848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.